The psychedelic trip produced by magic mushrooms can lift anxiety and depression in people dealing with life-threatening cancer, according to two clinical trials in the US.
Researchers from Johns Hopkins University in Baltimore and NYU Langone Medical Centre in New York carried out trials on a total of 80 volunteers with cancer who had reported symptoms of depression and anxiety.
Participants were given either a high dose of psilocybin, the active ingredient in magic mushrooms, o or a placebo. They then took part in a psychotherapy session during which they were encouraged to focus on their inner experiences while researchers monitored them. A few weeks later, the patients had a second session with the other drug.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
SUBSCRIBE & SAVE
Sign up for The Week's Free Newsletters
Join more than 350,000 subscribers and keep yourself informed with a selection of The Week’s most interesting, enlightening and entertaining stories - plus daily puzzles.
Join more than 350,000 subscribers and keep yourself informed with a selection of The Week’s most interesting, enlightening and entertaining stories - plus daily puzzles.
Latest Videos FromThe Week
In the Johns Hopkins study, 83 per cent of participants reported "decreases in measures of depression, anxiety and mood disturbance, and increases in measures of quality of life, life meaning, death acceptance and optimism", New Scientist reports.
The effect appears to be long lasting. "Six months after the final session of treatment, about 80 per cent of participants continued to show clinically significant decreases in depressed mood and anxiety," Medical Xpress reports.
The Guardian reports that the effects of magic mushrooms have been of interest to psychiatry since the 1950s, but the hardening of the US government's attitude towards recreational drug use after the late 1960s created "daunting legal and financial obstacles to running trials" with psychedelics.
A further practical difficulty in assessing hallucinogenics objectively is that participants in clinical trials are not supposed to know if they have received the real drug or a placebo, but the side effects of psychedelic drugs mean patients can tell if they have taken them.
Stephen Ross, the lead investigator on the NYU Langone trial, believes psilocybin's impact on patients' wellbeing far outstrips current treatment options, although he recognises the need for more research.
Between 40 and 50 per cent of cancer patients will develop depression or anxiety, but the current treatment options, such as antidepressants, "really don't work any better than placebo", he said.
If larger trials produce the same results, Ross says "psilocybin potentially could be rescheduled to become a prescription medication for cancer-related anxiety and depression".
